НовостиBenzingaRapport Therapeutics Announces That Topline Results From Its Phase 2 Trial Of RAP-219 In Adults With Acute Bipolar Mania Met Primary Endpoint Rapport Therapeutics Announces That Topline Results From Its Phase 2 Trial Of RAP-219 In Adults With Acute Bipolar Mania Met Primary Endpoint Benzinga 2026.10.20 10:09 (GMT+0) Открыть на Benzinga Другие новости
